PAREXEL CELEBRATES FIRST BACHELOR OF SCIENCE GRADUATES FROM ITS INTERNATIONAL CLINICAL RESEARCH PROGRAM - PAREXEL Academy™ provides pipeline of trained professionals to meet increasing demand for clinical research talent in the biopharmaceutical industry
Boston, MA, July 7, 2011—PAREXEL Academy, a leading provider of education and professional training for the biopharmaceutical industry in the field of clinical research, which is operated by PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, announced today that it has graduated the first class from its Bachelor of Science (BSc) in Clinical Research program. PAREXEL Academy, based in Berlin, Germany, launched the BSc program in 2008 to award one of the first internationally accredited undergraduate degrees in clinical research, which is validated by the University of Wales.
According to PAREXEL Academy Director Dr. Heidrun Bruchmann, “There is increasing demand for talent in the field of clinical research, driven by the growing complexity and globalization of the biopharmaceutical industry. PAREXEL had the foresight to create initiatives to address the need for a pipeline of properly trained clinical research professionals who could successfully navigate in a dynamic market.”
“Our focus is to design courses by industry specialists for industry specialists. We believe that international validation and accreditation of our degrees is critically important, and in this regard we truly value the contributions of the University of Wales. This BSc program reinforces our commitment to developing the next generation of clinical research professionals to make meaningful contributions in advancing the success of the biopharmaceutical industry in preventing and curing disease,” said Dr. Bruchmann.
“I would like to extend my warm congratulations to PAREXEL Academy’s first ever graduating cohort of University of Wales students. We hope that our cooperative relationship with PAREXEL will contribute to a broader knowledge base in global clinical development and I wish these bright new graduates every success for the future,” said The University of Wales Vice Chancellor Professor Marc Clement.
The PAREXEL Academy BSc program was designed as a modular and interdisciplinary course of study to be completed over three years or in six semesters. The curriculum incorporates an international focus, sound scientific basis, and blend of theory and practice, including a five-month work placement requirement. The goal of the program is to prepare students for positions in the global clinical research market, with expectations that graduates will work at biopharmaceutical companies, clinical research organizations, or coordination centers for clinical trials.
Offering professional training since 2001 PAREXEL Academy provides postgraduate courses for clinical research associates, study nurses, and study coordinators. Training courses are also provided for investigators with special emphasis on conducting clinical trials in accordance with International Conference on Harmonization-Good Clinical Practice (ICH-GCP) standards. For more information about PAREXEL Academy visit: http://www.PAREXEL-akademie.de/english/.
# # #
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 10,350 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated restructuring charge of approximately $15 million over the fourth quarter of Fiscal Year 2011 as well as the first and second quarters of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 as filed with the SEC on May 10, 2011, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.